The Quantellect read.As of Nov 19, 2026, 3 active firms cover Pharming Group NV: 3 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $37.00 to $41.00, so the covering firms are broadly aligned. The average target of $38.67 sits 210% above the current $12.48. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.01 next quarter toward $0.18 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy3100%
Neutral00%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$38.67
+209.8% upside
Average target across 3 active firms as of Nov 19, 2026 vs $12.48 current
Highest Target$41.00
Average Target$38.67
Lowest Target$37.00
Detailed analyst forecasts for PHAR
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 3 of 3 active firms rate PHAR a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
PHAR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.01
Range $-0.01 – $-0.01 · 1 analysts · -86% YoY
Next period, 1 analysts expect Pharming Group NV to earn $-0.01 a share (range $-0.01 – $-0.01), versus $-0.07 a year earlier. Full-year consensus is $0.26, growing to $0.18 the year after.
REVENUE · NEXT QUARTER
$77.0M
Range $77.0M – $77.0M · 1 analysts · +6% YoY
Revenue is expected to reach $77.0M (range $77.0M – $77.0M), +6.3% year-over-year. Full-year consensus is $387.3M, rising to $422.0M next year.
Top analysts covering Pharming Group NV
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PHAR.
#1
Jeff Jones
Oppenheimer · Rank #320
Buy
$40.00+220.4% to target
Overall win rate
32%
+ Follow
#2
Joseph Pantginis
HC Wainwright & Co. · Rank #373
Buy
$37.00+196.4% to target
Overall win rate
34%
+ Follow
#3
WI
Whitney Ijem
Canaccord Genuity · Rank #392
Buy
$38.00+204.4% to target
Overall win rate
35%
+ Follow
#4
MC
Michael Carrier
Oppenheimer
Buy
$39.00+212.4% to target
Coverage
—
+ Follow
#5
LC
Lucy Codrington
Jefferies
Buy
$14.00+12.2% to target
Coverage
—
+ Follow
PHAR stock forecast FAQ
What is PHAR's average 12-month price target?+
The 3 active firms with a live target average $38.67 for Pharming Group NV over the next 12 months, ranging from a $41.00 high to a $37.00 low, as of Nov 19, 2026.
Is PHAR stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for PHAR?+
The Street-high target is $41.00 (Oppenheimer), and the Street-low is $37.00 (HC Wainwright & Co.). The average of all 3 active-firm targets is $38.67.
How many active Wall Street firms cover PHAR?+
3 active firms have a recognized rating on Pharming Group NV as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering PHAR?+
Among analysts who currently cover PHAR, Jeff Jones of Oppenheimer has the strongest overall Quantellect track record (Rank #320). Their current call is Buy with a $40.00 target.
What is Pharming Group NV's projected EPS for next quarter?+
The consensus estimate is $-0.01 per share (range $-0.01 – $-0.01) across 1 analysts. Full-year EPS is projected at $0.26, rising to $0.18 the following year.
How much revenue is Pharming Group NV expected to report next quarter?+
Consensus revenue is $77.0M (range $77.0M – $77.0M). Full-year revenue is projected at $387.3M, growing to $422.0M next year.
Have analysts been upgrading or downgrading PHAR lately?+
As of Nov 19, 2026, 3 of 3 active firms rate PHAR a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PHAR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.